Targeting the Oncogenic Drivers of Rhabdomyosarcoma
Anticipated goals: Agreement and Update on: 1.) Collaboration to validate prognostic markers in rhabdomyosarcoma. 2.) Plan for genomic investigation for every sample entered on national/international trials. 3.) Collaboration for data unification and sharing of samples. 4. Plan for clinical trials of targeted agents in rhabdomyosarcoma.
Dr. Javed Khan, (301) 480-0314, email@example.com
National Cancer Institute
Office of Rare Diseases Research
From the National Center for Advancing Translational Sciences
From the National Institutes of Health